Journal Mobile Options
Table of Contents
Vol. 67, No. 5-6, 2004
Issue release date: January 2005

Clinicopathological Features of Extranodal Lymphomas: Kuwait Experience

Temmim L. · Baker H. · Amanguno H. · Madda J.P. · Sinowatz F.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

A total of 935 patients with extranodal non-Hodgkin lymphoma (NHL) diagnosed in the period between January 1985 and December 2000 in Kuwait Cancer Center, serving the whole population of Kuwait, were used to describe the clinicopathological and epidemiological features of extranodal lymphomas in Kuwait. Extranodal lymphomas accounted for 45% of all NHL observed during this time. All NHL cases from Kuwait Cancer registry were analyzed and pathologically reclassified using the latest WHO (2000) classification. The most common lymphoma observed was diffuse large B-cell lymphoma (58.60%) followed by Burkitt´s lymphoma (BL) (3.80%). In the pediatric group, BL comprises more than two thirds of all patients (77.20%). The most common extranodal sites were stomach (19.70%) and skin (17.80%) in the adult group, large intestine (29.80%) and small intestine (19.30%) in the pediatric age group. The majority (73.40%) of adult extranodal lymphomas was in stage IE–IIE and had a very good prognosis. On the contrary, the majority of pediatric extranodal lymphomas were found to be in stage III and IV. Variations in treatment policies (single agent or combined chemotherapy, radiotherapy, combined modality treatment) adopted and changed during the time period of 16 years of this retrospective study were documented.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Guerney KA, Cartwright RA, Gilman EEA: Descriptive epidemiology of gastrointestinal non-Hodgkin’s lymphoma on a population-based registry. Br J Cancer 1999;79:1929–1934.
  2. Hauke RJ, Armitage JO: A new approach to non-Hodgkin’s lymphoma. Intern Med 2000;39:197–208.
  3. Longo DL: Non-Hodgkin’s lymphoma. Curr Opin Hematol 1994;1:295–302.
  4. Newton R, Ferlay J, Beral V, Devesa SS: The epidemiology of non-Hodgkin lymphoma: Comparison of nodal and extranodal sites. Int J Cancer 1997;72:923–930.
  5. Weisenburger DD: Epemiology on non-Hodgkin’s lymphoma: Recent findings regarding an emerging epidemic. Ann Oncol 1994;5:9–24.
  6. Uppenkamp M, Feller AC: Classification of malignant lymphoma: Onkologie 2002;25:563–570.
  7. Freeman C, Berg JW, Cutler SJ: Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252–260.
  8. Otter R, Gerrits WBJ, Sandt MMVD, Hermans J, Willemez R: The Lymphoma Study Group. Primary extranodal non Hodgkin´s lymphomas. A survey of population-based registry. Eur J Cancer clin Oncol 1989;25:1203–1210.
  9. D’Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup P, Pedersen M, Jensen MK, Johansen P, Andersen E, Back B, Sorensen E: Clinico-pathological features and prognostic factors in extranodal Hodgkin lymphomas. Eur J Cancer 1991;27:1201–1208.
  10. Krol AD, leCessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM: Primary extranodal non-Hodkin´s lmyphoma (NHL): The impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003;14:131–139.
  11. Zeeb H, Blettner M: Increasing incidence and mortality of non-Hodgkin lymphomas. An epidemiological review of recent studies on risk factors for non-Hodgkin lymphoma. Med Klin 2001;96:87–100.
  12. Gospodarowicz MK, Sufcliffe SB: The extranodal lymphomas. Semin Radiat Oncol 1995;5:281–300.

    External Resources

  13. Harris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: The World Health Organization classification of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, 1997. Histopathology 2000;36:69–87.
  14. Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin´s lymphoma: Distribution of the major subtypes differ by geographic locations. Non-Hodgkin´s lymphoma classification project. Ann Oncol 1998;9:717–720.
  15. Ohshima K, Suzumiya J, Kikuchi M: The World Health Organization classification of malignant lymphoma incidence and clinical prognosis in HTLV-1-endemic area of Fukuoka. Pathol Int 2002;52:1–12.
  16. Bamanikar S, Thunhold S, Devi KR, Bamanikar A: The pattern of malignant lymphoma in Oman. J Trop Med Hyg 1995;98:351–354.
  17. Castella A, Joshi S, Raaschou T, Mason N: Acta Oncol 2001;40:660–664.
  18. Shome DK, George SM, Al-Hilli F, Satir AA: Spectrum of malignant lymphomas in Bahrain. Leitmotif of a regional pattern. Saudi Med J 2004;25:164–167.
  19. Baker H, Al-Jarallah M, Manguno H, Temmim L, Madda JP, Sinowatz F: Clinical characteristics and pathological classification of non-Hodgkin’s lymphoma in Kuwait. Results of a colloborative study with the International Lymphoma Study Group (ILSG). Leuk Lymphoma 2004;45:1865–1871.
  20. Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N: The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarkers Prev 1998;7:43–51.

    External Resources

  21. Groves FD, Linet MS, Travis LB, Devesa SS: Cancer surveillance series: Non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240–1251.
  22. Ducreux M, Boutron MC, Piard F, Carli PM, Faivre J: A 15-year series of gastrointestinal non-Hodgkin’s lymphomas: A population-based study. Br J Cancer 1998;77:511–514.
  23. Stiller CA, Parkin DM: International variation in the incidence of childhood lymphomas. Paediatr Perinat Epidemiol 1990;4:303–324.
  24. Mottl H, Bajcova V, Nemec J, Shenmari SA, Awadi SA: High survial rate in childhood Non-Hodgkin lymphoma without CNS involvement: Results of BFM 95 study in Kuwait. Pediatr Hematol Oncol 2003;20:103–110.
  25. Penn I: Incidence and treatment of neoplasias after transplantation. J Heart Lung Transplant 2001;12:328–336.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50